Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company specializing in therapies for difficult-to-treat cancers, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The conference will be held from September 9-11, 2024, with Actuate scheduled to present on Tuesday, September 10, 2024, at 4:00 PM ET.
The company's presentation will focus on its innovative approach to inhibiting glycogen synthase kinase-3 beta (GSK-3β), targeting cancers such as pancreatic cancer and Ewing sarcoma. The presentation will be available via webcast in the Investor section of Actuate's website. Additionally, Actuate's management team will be available for one-on-one meetings during the conference.
Actuate Therapeutics (NASDAQ: ACTU), un'azienda biofarmaceutica in fase clinica specializzata in terapie per tumori difficili da trattare, ha annunciato la sua partecipazione alla 26a Conferenza Globale sugli Investimenti Annuale H.C. Wainwright a New York City. La conferenza si svolgerà dal 9 all'11 settembre 2024, con Actuate programmata per presentare martedì 10 settembre 2024, alle 16:00 ET.
La presentazione dell'azienda si concentrerà sul suo approccio innovativo per inibire la glicogeno sintasi chinasi-3 beta (GSK-3β), mirando a tumori come il cancro pancreatico e il sarcoma di Ewing. La presentazione sarà disponibile tramite webcast nella sezione Investor del sito web di Actuate. Inoltre, il team di gestione di Actuate sarà disponibile per incontri individuali durante la conferenza.
Actuate Therapeutics (NASDAQ: ACTU), una compañía biofarmacéutica en etapa clínica especializada en terapias para cánceres difíciles de tratar, anunció su participación en la 26ª Conferencia Global Anual de Inversión H.C. Wainwright en Nueva York. La conferencia se llevará a cabo del 9 al 11 de septiembre de 2024, con Actuate programada para presentar el martes 10 de septiembre de 2024, a las 4:00 PM ET.
La presentación de la compañía se centrará en su enfoque innovador para inhibir la quinasa de síntesis de glucógeno-3 beta (GSK-3β), enfocándose en cánceres como cáncer de páncreas y sarcoma de Ewing. La presentación estará disponible a través de un webcast en la sección de Inversores del sitio web de Actuate. Además, el equipo de gestión de Actuate estará disponible para reuniones uno a uno durante la conferencia.
Actuate Therapeutics (NASDAQ: ACTU)는 치료하기 어려운 암을 위한 치료법을 전문으로 하는 임상 단계의 바이오 제약 회사로서 뉴욕시에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참가한다고 발표했습니다. 이 회의는 2024년 9월 9일부터 11일까지 진행되며, Actuate는 2024년 9월 10일 화요일 오후 4시 ET에 발표할 예정입니다.
회사의 발표는 글리코겐 합성 효소 키나제-3 베타 (GSK-3β) 억제에 대한 혁신적인 접근 방식에 초점을 맞추며 췌장암 및 유잉 육종과 같은 암을 겨냥하고 있습니다. 발표는 Actuate 웹사이트의 투자자 섹션을 통해 웹캐스트로 제공됩니다. 또한, Actuate의 경영진은 회의 중 1:1 미팅을 위해 참석할 예정입니다.
Actuate Therapeutics (NASDAQ: ACTU), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les thérapies pour les cancers difficiles à traiter, a annoncé sa participation à la 26ème Conférence Globale Annuelle d'Investissement H.C. Wainwright à New York. La conférence se tiendra du 9 au 11 septembre 2024, avec Actuate prévu pour présenter le mardi 10 septembre 2024, à 16h00 ET.
La présentation de l'entreprise se concentrera sur son approche innovante pour inhiber la kinase de synthèse du glycogène-3 beta (GSK-3β), visant des cancers tels que le cancer du pancréas et le sarcome d'Ewing. La présentation sera disponible par webcast dans la section Investisseur du site Internet d'Actuate. De plus, l'équipe de direction d'Actuate sera disponible pour des réunions individuelles pendant la conférence.
Actuate Therapeutics (NASDAQ: ACTU), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien für schwer behandelbare Krebserkrankungen spezialisiert hat, gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz H.C. Wainwright in New York City bekannt. Die Konferenz findet vom 9. bis 11. September 2024 statt, wobei Actuate am Dienstag, den 10. September 2024, um 16:00 Uhr ET präsentieren wird.
Die Präsentation des Unternehmens wird sich auf seinen innovativen Ansatz zur Hemmung der Glykogensynthasekinase-3 beta (GSK-3β) konzentrieren, der auf Krebserkrankungen wie Bauchspeicheldrüsenkrebs und Ewing-Sarkom abzielt. Die Präsentation wird über einen Webcast im Investorenbereich der Website von Actuate verfügbar sein. Darüber hinaus wird das Management-Team von Actuate während der Konferenz für Einzelgespräche zur Verfügung stehen.
- None.
- None.
CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma, through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. In addition, the management team will be available for one-on-one meetings during the conference.
Details on the presentation:
Format: Corporate Presentation
Date: Tuesday, September 10, 2024
Time: 4:00 PM ET
Webcast Link: click here
The webcast of the presentation will be accessible in the Investor section of the Actuate website
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DDR pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
FAQ
When is Actuate Therapeutics presenting at the H.C. Wainwright 26th Annual Global Investment Conference?
Where can I watch the Actuate Therapeutics presentation at the H.C. Wainwright conference?
What type of cancers is Actuate Therapeutics focusing on?
What is the stock symbol for Actuate Therapeutics?
What innovative approach is Actuate Therapeutics using in their cancer therapies?
Will Actuate Therapeutics be available for meetings at the H.C. Wainwright conference?
